Page last updated: 2024-11-13

mk-8742

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

elbasvir: inhibits NS5A protein of hepatitis C virus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

elbasvir : A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID71661251
CHEMBL ID3039514
CHEBI ID132967
SCHEMBL ID17429773
MeSH IDM000595363

Synonyms (42)

Synonym
mk 8742
mk8742
mk-8742
1370468-36-2
methyl {(2s)-1-[(2s)-2-{4-[(6s)-3-{2-[(2s)-1-{(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1h-imidazol-4-yl}-6-phenyl-6h-indolo[1,2-c][1,3]benzoxazin-10-yl]-1h-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate
CHEBI:132967
elbasvir
S5652
CHEMBL3039514
elbasvir [usan:inn]
dimethyl n,n'-(((6s)-6-phenylindolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-pyrrolidine-2,1-diyl((2s)-3-methyl-1-oxobutane-1,2-diyl)))dicarbamate
unii-632l571ydk
methyl ((1s)-1-(((2s)-2-(4-((6s)-10-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1h-imidazol-4-yl)-6-phenyl-6h-indolo(1,2-c)(1,3)benzoxazin-3-yl)-1h-imidazol-2-yl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)carbamate
carbamic acid, n,n'-(((6s)-6-phenyl-6h-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, c,c'-dimethyl ester
632l571ydk ,
elbasvir [jan]
elbasvir [who-dd]
elbasvir [orange book]
elbasvir [inn]
elbasvir [mi]
zepatier component of elbasvir
elbasvir [usan]
elbasvir component of zepatier
HY-15789
CS-5332
SCHEMBL17429773
AKOS030526458
elbasvir(mk-8742)
DB11574
dimethyl ((2s,2's)-((2s,2's)-2,2'-(5,5'-((s)-6-phenyl-6h-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate
EX-A2889
mk8742; elbasvir
Q19904043
methyl ((s)-1-((s)-2-(4-((s)-10-(2-((s)-1-((methoxycarbonyl)-l-valyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-6-phenyl-6h-benzo[5,6][1,3]oxazino[3,4-a]indol-3-yl)-1h-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
carbamic acid, n,n'-[[(6s)-6-phenyl-6h-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl[(1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, c,c'-dimethyl ester
methyl n-[(2s)-1-[(2s)-2-[5-[(6s)-3-[2-[(2s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]-6-phenyl-6h-indolo[1,2-c][1,3]benzoxazin-10-yl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
CCG-270552
NCGC00510317-02
bdbm50531952
EN300-27736678
methyl n-[(2s)-1-[(2s)-2-{5-[(9s)-14-{2-[(2s)-1-[(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1h-imidazol-5-yl}-9-phenyl-8-oxa-10-azatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(17),2(7),3,5,11(16),12,14-heptaen-5-yl]-1h-imidazol-2-
dimethyl((2s,2's)-((2s,2's)-2,2'-(5,5'-((s)-6-phenyl-6h-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1h-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No patient discontinued due to an adverse event or laboratory abnormality."( Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E, 2015
)
0.63
" Adverse events reported in more than 10% of patients were fatigue (66 patients, 26% [95% CI 21-32]), headache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19])."( Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J, 2015
)
0.63
" The most common adverse events were fatigue (29; 13%), headache (27; 12%), and nausea (20; 9%)."( Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Barr, E; Bloch, M; Gress, J; Katlama, C; Klopfer, S; Lalezari, J; Mallolas, J; Matthews, GV; Nelson, M; Nguyen, BY; Orkin, C; Platt, HL; Robertson, MN; Rockstroh, JK; Saag, MS; Shaughnessy, M; Sulkowski, M; Wahl, J; Zamor, PJ, 2015
)
0.66
" Serious adverse events were reported in 3% (8 of 264) patients and no patient had a decompensation-related event."( Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J, 2017
)
0.46
" The safety profile was similar across treatment arms, with adverse events tending to occur more frequently among participants receiving RBV."( Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E, 2018
)
0.48
" There were no severe adverse events associated with the treatment."( Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Abe, H; Asano, T; Atsukawa, M; Deguchi, A; Fujioka, S; Hiraoka, A; Iio, E; Ishikawa, T; Itobayashi, E; Iwakiri, K; Kato, K; Kondo, C; Kumada, T; Masaki, T; Michitaka, K; Mikami, S; Moriya, A; Ogawa, C; Okubo, H; Okubo, T; Senoh, T; Shimada, N; Tada, T; Takaguchi, K; Tamai, H; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T; Yoneyama, H, 2018
)
0.48
" During the study, we did not record any serious adverse drug reaction or drug interaction and no patients discontinued the treatment."( Efficacy and Safety of Elbasvir-Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real-Life Clinical Practice.
Caroleo, B; Colangelo, L; De Sarro, G; Gallelli, L; Perticone, M, 2018
)
0.48
"Treatments for hepatitis C virus (HCV) have advanced greatly, becoming more efficacious with fewer adverse events, due to the availability of direct-acting antiviral agents, which target specific steps in the HCV life cycle."( Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
Morikawa, K; Nakamura, A; Sakamoto, N; Shimazaki, T, 2018
)
0.48
" We collected data on on-treatment adverse events (AEs), severe AEs, and laboratory abnormalities."( Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Aoufi-Rabih, S; Dixit, V; Fabrizi, F; Garcia-Agudo, R; Mendizabal, M; Ridruejo, E; Silva, M,
)
0.13
" Drug-related adverse events occurred in 42% (n = 22) and 50% (n = 32) of participants receiving 8 and 12 weeks of treatment, respectively."( Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
Ahmed, SNS; Alric, L; Asante-Appiah, E; Asselah, T; Bronowicki, JP; Brown, D; Guidoum, A; Haber, BA; Hagen, K; Hall, JD; Hanna, GJ; Hezode, C; Hwang, P; Larrey, D; Leroy, V; Loustaud-Ratti, V; Nguyen-Khac, E; Ozenne, V; Pol, S; Robertson, MN; Serfaty, L; Su, FH; Talwani, R; Tran, A, 2020
)
0.56
" All the studies that reported the sustained virologic response (SVR) and adverse events of DAAs in HIV/HCV co-infected patients were included."( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020
)
0.56
"6%) were the most effective combinations for HIV/HCV co-infected patients, with SVR rates of approximately 94% and above while severe adverse events were rare."( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020
)
0.56
" GZR/EBR ± RBV was the optimal combination recommended for HIV/HCV co-infected patients based on the excellent treatment effects and insignificant adverse events."( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020
)
0.56
" Retrospective analysis of the fractions of patients that achieved sustained virological response (SVR) was performed, and the incidence of adverse events was noted."( Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2021
)
0.62
"1%) were common adverse events."( Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2021
)
0.62
"3%) reported ≥1 adverse event (AE) and 491 had AEs (28."( Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
Brown, DD; Haber, BA; Klopfer, SO; Kwo, P; Nangia, G; Reddy, KR; Robertson, MN; Vierling, JM, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" These studies evaluated the safety and pharmacokinetic interactions between elbasvir (EBR) and grazoprevir (GZR) and ethinyl estradiol/levonorgestrel (EE/LNG)."( No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Butterton, JR; Caro, L; Feng, HP; Guo, Z; Huang, X; Ma, J; Mangin, E; Marshall, WL; O'Reilly, TE; Panebianco, D; Talaty, J; Yeh, WW, 2017
)
0.46
" Participants with mild, moderate, or severe HI and controls (aged 18 to 65 years) matched for race, age, sex, and body mass index were enrolled in a 3-part, open-label, sequential-panel pharmacokinetic study."( Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Angus, P; Butterton, JR; Caro, L; Fandozzi, C; Fraser, IP; Gane, E; Guo, Z; Ho, M; Iwamoto, M; Marbury, T; Panebianco, D; Reitmann, C; Smith, WB; Talaty, J; Uemura, N; Wenning, L; Yeh, WW, 2017
)
0.46
"Participants with mild, moderate, or severe hepatic impairment and age-, sex-, and weight-matched healthy controls were enrolled in a 3-part, open-label, sequential-panel, single-dose pharmacokinetic study."( Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Garrett, G; Huang, X; Iwamoto, M; Lasseter, KC; Liu, F; Marbury, T; Marshall, WL; Panebianco, D; Preston, RA; Wenning, L; Yeh, WW, 2018
)
0.48
"This study evaluated the single- and multiple-dose pharmacokinetic (PK) variables of elbasvir and grazoprevir in healthy Chinese individuals."( A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
Cheung, TT; Feng, HP; Li, W; Ling Lam, KS; Mu, S; Wang, J; Wang, Z; Yan Chiu, JW; Yeh, WW; Yuen, MF; Yung Cheung, BM; Zhao, XM, 2018
)
0.48
"To describe the phase 1 and population pharmacokinetic investigations that support dosing recommendations for elbasvir/grazoprevir (EBR/GZR) in hepatitis C virus-infected people with advanced chronic kidney disease."( Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW, 2019
)
0.51
" Population pharmacokinetic analyses from the phase 3 C-SURFER study (PN052, NCT02092350) were also conducted."( Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW, 2019
)
0.51
" Pharmacokinetic similarity criteria (90% CIs lie within 70%-143% acceptance range) were used for AUC0-∞ and AUC0-72."( Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
Abbink, EJ; Burger, DM; Colbers, A; Drenth, JPH; Pijnenburg, DWM; van Seyen, M, 2020
)
0.56
"Mean plasma concentration-time curves of elbasvir and grazoprevir showed similar pharmacokinetic profiles."( Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
Abbink, EJ; Burger, DM; Colbers, A; Drenth, JPH; Pijnenburg, DWM; van Seyen, M, 2020
)
0.56
" This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations similar to those seen in adults receiving the approved fixed-dose combination regimen of EBR/GZR."( Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Alkhouri, N; Balistreri, WF; Blondet, N; Caro, L; Castronuovo, P; Du, L; Fischler, B; Gonzalez-Peralta, RP; Grandhi, A; Haber, BA; Jonas, MM; Lang, T; Majda-Stanislawska, E; Mutschler, F; Pawlowska, M; Romero, R; Rosenbloom, DIS; Rosenthal, P; Sluzewski, W; Squires, RH; Wirth, S, 2023
)
0.91
" Pharmacokinetic data were used to bridge efficacy and safety data from adults to children in a stepwise (oldest to youngest) manner."( Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Alkhouri, N; Balistreri, WF; Blondet, N; Caro, L; Castronuovo, P; Du, L; Fischler, B; Gonzalez-Peralta, RP; Grandhi, A; Haber, BA; Jonas, MM; Lang, T; Majda-Stanislawska, E; Mutschler, F; Pawlowska, M; Romero, R; Rosenbloom, DIS; Rosenthal, P; Sluzewski, W; Squires, RH; Wirth, S, 2023
)
0.91
"Pediatric EBR/GZR pharmacokinetic models were successfully developed based on complex adult population pharmacokinetic models."( Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Alkhouri, N; Balistreri, WF; Blondet, N; Caro, L; Castronuovo, P; Du, L; Fischler, B; Gonzalez-Peralta, RP; Grandhi, A; Haber, BA; Jonas, MM; Lang, T; Majda-Stanislawska, E; Mutschler, F; Pawlowska, M; Romero, R; Rosenbloom, DIS; Rosenthal, P; Sluzewski, W; Squires, RH; Wirth, S, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"Elbasvir or grazoprevir co-administered with raltegravir or dolutegravir resulted in no clinically meaningful drug-drug interactions and was generally well tolerated."( Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Fraser, I; Guo, Z; Huang, X; Iwamoto, M; Jumes, P; Ma, J; Mangin, E; Marshall, WL; Panebianco, D; Ross, LL; Talaty, J; Yeh, WW, 2019
)
0.51
"The assessment of drug-drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC)."( Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Cheng, PN; Liu, CJ; Lo, CC; Tseng, IH; Tseng, KC, 2020
)
0.56
" In this study, we evaluated the drug-drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and grazoprevir (GZR) with statins."( Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Herein, we describe research efforts that led to the discovery of a series of fused tricyclic core containing HCV NS5A inhibitors such as 24, 39, 40, 43, and 44 which have pan-genotype activity and are orally bioavailable in the rat."( Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Agrawal, S; Asante-Appiah, E; Chen, KX; Chen, L; Coburn, CA; Dwyer, MP; Fells, J; Hu, B; Ingravallo, P; Ji, T; Jiang, Y; Kong, R; Kozlowski, JA; Liu, R; Meinke, PT; Nair, AG; Njoroge, GF; Nomeir, A; Rosenblum, SB; Selyutin, O; Tong, L; Wong, M; Xia, E; Yang, DY; Yu, W; Zeng, Q; Zhai, Y; Zhong, B, 2016
)
0.43
" However, further optimization of their oral bioavailability is still needed in order to advance them for further development."( Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
Agrawal, S; Asante-Appiah, E; Chen, S; Hao, J; Hu, B; Kozlowski, JA; Lei, Z; Liu, R; Rokosz, L; Yu, W; Zhong, B, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Randomisation was by presence or absence of ribavirin, 8 or 12 weeks of treatment, and dosage of elbasvir."( Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E, 2015
)
0.63
"The first three UV spectrophotometric methods have been developed of simultaneous determination of two new FDA approved drugs namely; elbasvir and grazoprevir in their combined pharmaceutical dosage form."( Application of different spectrophotometric methods for simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation.
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A, 2018
)
0.48
" The two drugs were co-formulated for treatment of hepatitis C virus in their combined pharmaceutical dosage form."( Simultaneous Determination of Elbasvir and Grazoprevir in Their Pharmaceutical Preparation Using High-Performance Liquid Chromatographic Method.
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Dosoky, M; El-Olemy, A, 2018
)
0.48
" Additionally it was possible to reduce prednisolone dosage to 5 mg/day."( Hepatitis C virus infection: 'beyond the liver'.
Arrais de Castro, R; Borges-Costa, J; Tato Marinho, R; Vilas, P, 2018
)
0.48
"To describe the phase 1 and population pharmacokinetic investigations that support dosing recommendations for elbasvir/grazoprevir (EBR/GZR) in hepatitis C virus-infected people with advanced chronic kidney disease."( Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW, 2019
)
0.51
" No dosage adjustment of EBR/GZR is required in people with any degree of renal impairment, including those receiving dialysis."( Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW, 2019
)
0.51
"Artificial neural networks and genetic algorithm artificial neural networks, chemometric assisted spectrophotometric models, were developed for the quantitative analysis of elbasvir and grazoprevir in their newly FDA approved pharmaceutical dosage form."( Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models.
Abdelazim, AH; Shahin, M; Zeid, AM, 2021
)
0.62
"Steady-state plasma exposures were achieved by week 4 for EBR and GZR in all cohorts and daily dosing achieved geometric mean steady-state area under the concentration-time curve at 0-24 hours that fell within comparability bounds established for adults."( Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
Alkhouri, N; Balistreri, WF; Blondet, N; Caro, L; Castronuovo, P; Du, L; Fischler, B; Gonzalez-Peralta, RP; Grandhi, A; Haber, BA; Jonas, MM; Lang, T; Majda-Stanislawska, E; Mutschler, F; Pawlowska, M; Romero, R; Rosenbloom, DIS; Rosenthal, P; Sluzewski, W; Squires, RH; Wirth, S, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
hepatitis C virus nonstructural protein 5A inhibitorAny inhibitor of hepatitis C virus nonstructural protein 5A.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
L-valine derivativeA proteinogenic amino acid derivative resulting from reaction of L-valine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-valine by a heteroatom.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
N-acylpyrrolidine
organic heterotetracyclic compound
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nonstructural protein 5A EC50 (µMol)0.00060.00000.13758.1000AID1313143; AID1313144; AID1624665; AID1624666; AID1624667; AID1624668; AID1624669
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)EC90 (µMol)0.02800.02800.02800.0280AID1323662
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)EC90 (µMol)0.02800.02800.02800.0280AID1323662
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)EC90 (µMol)0.02800.02800.02800.0280AID1323662
Nonstructural protein 5A EC90 (µMol)0.00730.00000.00730.0280AID1323662; AID1323663; AID1338541; AID1338543; AID1338547; AID1338548; AID1338549; AID1370127; AID1370129; AID1370130; AID1370132; AID1370133; AID1370134; AID1627266; AID1627267; AID1627268; AID1627269; AID1632816; AID1632817; AID1632818; AID1632819; AID1632820; AID1632821; AID1632822; AID1632823
Genome polyproteinHepatitis C virus (isolate NZL1)EC90 (µMol)0.00010.00010.00010.0001AID1370131
P2X purinoceptor 7Homo sapiens (human)EC90 (µMol)0.00100.00100.00100.0010AID1627269
Genome polyproteinHepatitis C virus (isolate Con1)EC90 (µMol)0.00000.00000.00000.0000AID1370128
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (75)

Processvia Protein(s)Taxonomy
MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
cell morphogenesisP2X purinoceptor 7Homo sapiens (human)
phagolysosome assemblyP2X purinoceptor 7Homo sapiens (human)
T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein phosphorylationP2X purinoceptor 7Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 7Homo sapiens (human)
response to ischemiaP2X purinoceptor 7Homo sapiens (human)
membrane protein ectodomain proteolysisP2X purinoceptor 7Homo sapiens (human)
phospholipid transfer to membraneP2X purinoceptor 7Homo sapiens (human)
vesicle budding from membraneP2X purinoceptor 7Homo sapiens (human)
inflammatory responseP2X purinoceptor 7Homo sapiens (human)
mitochondrion organizationP2X purinoceptor 7Homo sapiens (human)
cell surface receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
protein secretionP2X purinoceptor 7Homo sapiens (human)
response to xenobiotic stimulusP2X purinoceptor 7Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 7Homo sapiens (human)
response to zinc ionP2X purinoceptor 7Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of gene expressionP2X purinoceptor 7Homo sapiens (human)
glutamate secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of glutamate secretionP2X purinoceptor 7Homo sapiens (human)
gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
synaptic vesicle exocytosisP2X purinoceptor 7Homo sapiens (human)
protein processingP2X purinoceptor 7Homo sapiens (human)
plasma membrane phospholipid scramblingP2X purinoceptor 7Homo sapiens (human)
sensory perception of painP2X purinoceptor 7Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 7Homo sapiens (human)
protein catabolic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of bone mineralizationP2X purinoceptor 7Homo sapiens (human)
bleb assemblyP2X purinoceptor 7Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
response to lipopolysaccharideP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 alpha productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 beta productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionP2X purinoceptor 7Homo sapiens (human)
collagen metabolic processP2X purinoceptor 7Homo sapiens (human)
response to ATPP2X purinoceptor 7Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 7Homo sapiens (human)
positive regulation of monoatomic ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
T cell proliferationP2X purinoceptor 7Homo sapiens (human)
T cell homeostasisP2X purinoceptor 7Homo sapiens (human)
NAD transportP2X purinoceptor 7Homo sapiens (human)
negative regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
positive regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
negative regulation of bone resorptionP2X purinoceptor 7Homo sapiens (human)
negative regulation of cell volumeP2X purinoceptor 7Homo sapiens (human)
positive regulation of glycolytic processP2X purinoceptor 7Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 7Homo sapiens (human)
pore complex assemblyP2X purinoceptor 7Homo sapiens (human)
skeletal system morphogenesisP2X purinoceptor 7Homo sapiens (human)
homeostasis of number of cells within a tissueP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein secretionP2X purinoceptor 7Homo sapiens (human)
defense response to Gram-positive bacteriumP2X purinoceptor 7Homo sapiens (human)
release of sequestered calcium ion into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of cytoskeleton organizationP2X purinoceptor 7Homo sapiens (human)
response to calcium ionP2X purinoceptor 7Homo sapiens (human)
response to electrical stimulusP2X purinoceptor 7Homo sapiens (human)
mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
membrane depolarizationP2X purinoceptor 7Homo sapiens (human)
positive regulation of mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionP2X purinoceptor 7Homo sapiens (human)
T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
cellular response to ATPP2X purinoceptor 7Homo sapiens (human)
cellular response to dsRNAP2X purinoceptor 7Homo sapiens (human)
reactive oxygen species metabolic processP2X purinoceptor 7Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
extrinsic apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
positive regulation of bleb assemblyP2X purinoceptor 7Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 7Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 7Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 7Homo sapiens (human)
protein bindingP2X purinoceptor 7Homo sapiens (human)
ATP bindingP2X purinoceptor 7Homo sapiens (human)
identical protein bindingP2X purinoceptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmP2X purinoceptor 7Homo sapiens (human)
mitochondrionP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
cell-cell junctionP2X purinoceptor 7Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 7Homo sapiens (human)
membraneP2X purinoceptor 7Homo sapiens (human)
neuromuscular junctionP2X purinoceptor 7Homo sapiens (human)
blebP2X purinoceptor 7Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 7Homo sapiens (human)
presynapseP2X purinoceptor 7Homo sapiens (human)
postsynapseP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID1323661Inhibition of HCV genotype 2b NS5A harboring methionine at position 31 after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1338548Inhibition of HCV genotype-1a NS5A Q30R mutant infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1303818Antiviral activity against HCV genotype 3a NC009824 assessed as decrease in HCV replicon RNA replication by taqman assay based cell based replicon method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
AID1649893Half life in human2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1632819Inhibition of HCV GT2b NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1338547Inhibition of HCV genotype-1b NS5A Y93H mutant infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1649892Inhibition of HCV NS3/4a protease2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1370133Inhibition of NS5A Y93H mutant in HCV genotype 1a H77 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1627269Inhibition of HCV genotype 1a NS5A L31V mutant assessed as reduction in viral RNA level by cell based real time PCR method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
AID1889300Aqueous solubility of the compound at pH 52022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
AID1323659Inhibition of HCV genotype 4a NS5A after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1632817Inhibition of HCV GT1b NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1338550Inhibition of HCV genotype-2a NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1303819Antiviral activity against HCV genotype 1a H77 expressing NS5A Y93H mutant infected in mouse HB1 cells assessed as decrease in HCV replicon RNA replication by taqman assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
AID1338553Inhibition of HCV genotype-6d NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1370131Inhibition of NS5A in HCV genotype 3a NZL1 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1338540Inhibition of HCV genotype-1a NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1338552Inhibition of HCV genotype-6 NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1338542Inhibition of HCV genotype-2b NS5A harboring methionine at position 31 infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1313143Inhibition of NS5A in HCV genotype 1a Y93H mutant2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1632816Inhibition of HCV GT1a NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1627268Inhibition of HCV genotype 1a NS5A Y93H mutant assessed as reduction in viral RNA level by cell based real time PCR method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
AID1649896Drug excretion in human urine2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1323660Inhibition of HCV genotype 3a NS5A after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1313141Inhibition of NS5A in HCV genotype 3a2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1889304Permeability in MDCK-II cells2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
AID1303816Antiviral activity against HCV genotype 1b Con1 assessed as decrease in HCV replicon RNA replication by taqman assay based cell based replicon method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
AID1303817Antiviral activity against HCV genotype 2a JFH assessed as decrease in HCV replicon RNA replication by taqman assay based cell based replicon method2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
AID1632818Inhibition of HCV GT2a NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1632822Inhibition of HCV GT1a NS5A Y93H mutant assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1632823Inhibition of HCV GT1a NS5A L31V mutant assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1370129Inhibition of NS5A in HCV genotype 2a JFH infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1627267Inhibition of wild type HCV genotype 2b NS5A assessed as reduction in viral RNA level by cell based real time PCR method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
AID1323662Inhibition of HCV genotype 1a NS5A Y93H mutant after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1338551Inhibition of HCV genotype-5a NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1313138Inhibition of NS5A in HCV genotype 1b2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1313142Inhibition of NS5A in HCV genotype 4a2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1889299Aqueous solubility of the compound at pH 1.82022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
AID1624666Inhibition of NS5A in HCV genotype 1b assessed as decrease in viral replication2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
AID1624668Inhibition of NS5A in HCV genotype 3a assessed as decrease in viral replication2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
AID1632820Inhibition of HCV GT3a NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1338546Inhibition of HCV genotype-1b NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1624667Inhibition of NS5A in HCV genotype 2a assessed as decrease in viral replication2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
AID1338541Inhibition of HCV genotype-1a NS5A Y93H mutant infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1323664Inhibition of HCV genotype 1a NS5A after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1627266Inhibition of wild type HCV genotype 1a NS5A assessed as reduction in viral RNA level by cell based real time PCR method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
AID1313139Inhibition of NS5A in HCV genotype 2a2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1338544Inhibition of HCV genotype-3a NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1323663Inhibition of HCV genotype 1a NS5A L31V mutant after 3 day incubation by RT-PCR-cell-based HCV replicon assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
AID1338545Inhibition of HCV genotype-4a NS5A infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1624669Inhibition of NS5A Y93H mutant in HCV genotype 1a assessed as decrease in viral replication2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
AID1313137Inhibition of NS5A in HCV genotype 1a2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1338549Inhibition of HCV genotype-1a NS5A Y93C mutant infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1649895Drug excretion in human feces2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1370132Inhibition of NS5A in HCV genotype 4a infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1370128Inhibition of NS5A in HCV genotype 1b Con1 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1632821Inhibition of HCV GT4a NS5A assessed as suppression of replicon RNA level by real-time PCR analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
AID1370130Inhibition of NS5A L31M mutant in HCV genotype 2b isolate JPUT971017 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1313140Inhibition of NS5A in HCV genotype 2b2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1313144Inhibition of NS5A in HCV genotype 1a L31V mutant2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
AID1370134Inhibition of NS5A L31V mutant in HCV genotype 1a H77 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1370127Inhibition of NS5A in HCV genotype 1a H77 infected in HB1 replicon cells assessed as decrease in viral replication by TaqMan-based assay2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
AID1303815Antiviral activity against HCV genotype 1a H77 infected in mouse HB1 cells assessed as decrease in HCV replicon RNA replication after 3 days by taqman assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
AID1624665Inhibition of NS5A in HCV genotype 1a assessed as decrease in viral replication2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
AID1338543Inhibition of HCV genotype-1a NS5A L31V mutant infected in human HuH7 cells by luciferase reporter gene assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (136)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's96 (70.59)24.3611
2020's40 (29.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.57 (24.57)
Research Supply Index5.19 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (26.24%)5.53%
Reviews23 (16.31%)6.00%
Case Studies9 (6.38%)4.05%
Observational7 (4.96%)0.25%
Other65 (46.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]